Goldman Sachs analyst Scott Fidel initiated coverage of Cigna (CI) with a Buy rating and $370 price target The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CI:
- Cigna price target raised to $354 from $340 at Wells Fargo
- Sector Spotlight: UnitedHealth shareholder proposes split of CEO, chair role
- Trump Trade: White House announces drug pricing deal with Pfizer
- Health Insurance subsidies central to government shutdown negotiation, WSJ says
- Trump says working on reducing cost of health insurance